SLC5A2 and type 2 diabetes mellitus: Our results add valuable insights into the impact of SGLT2 inhibitors on AF in real-world settings and underscore the importance of considering individual characteristics in clinical decision-making regarding GLD for T2D patients, with the aim of optimizing treatment outcomes and minimizing the risk of complications.